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myocardial infarction. J Am Coll Cardiol 2015;65:2211–21.REPLY: Analysis of Dual Antiplatelet TherapyWe thank Dr. Ganeshan and colleagues for their in-
terest in our paper (1). In our subgroup analysis of the
DAPT Study (Dual Antiplatelet Therapy Study) (1),
continued thienopyridine therapy beyond 12 months
after coronary stent placement provided consistent
reductions in ischemic endpoints while increasing
bleeding in patients presenting initially with or
without myocardial infarction. Although not included
in our original publication, we have performed the
sensitivity analysis requested by Ganeshan and col-
leagues, grouping unstable angina patients with
myocardial infarction patients (acute coronary syn-
drome [ACS] group). In this analysis, consistent re-
ductions in ischemic endpoints were again observed
with continued thienopyridine in both ACS and non-
ACS patients (ACS group: stent thrombosis hazard
ratio [HR]: 0.35; p < 0.001, myocardial infarction HR:
0.47; p < 0.001; non-ACS group: stent thrombosis HR:
0.25, p < 0.001, myocardial infarction HR: 0.61;
p ¼ 0.002; interaction p ¼ NS for both comparisons).
GUSTO (Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary
Arteries) moderate or severe bleeding was increased
with continued thienopyridine in both groups as well
(ACS group HR: 2.01; p ¼ 0.002; non-ACS group HR:
1.49; p ¼ 0.024; interaction p ¼ 0.31).
As Dr. Ganeshan and colleagues rightly point out,
our study was a post-hoc subgroup analysis of a
completed randomized clinical trial (2,3) and was not
speciﬁcally powered to assess the interactions pre-
sented. Its conclusions should be interpreted with
this in mind.A large fraction of eligible patients were not ran-
domized in the DAPT study, primarily due to patient
and provider preference. Among myocardial infarc-
tion patients, those who were eligible, but not ran-
domized, were similar in age, but were more often
women (38.3% vs. 31.8%; p < 0.001), nonwhite (12.7%
vs. 8.4%), and had higher rates of diabetes, prior
stroke, congestive heart failure, and prior coronary
revascularization (p < 0.001 for each), as compared
with those randomized in the study. Similar results
were observed among patients without myocardial
infarction. These ﬁndings suggest that the random-
ized patients were somewhat lower risk for recurrent
ischemic events than those who were enrolled. It is
likely that had these eligible subjects also been ran-
domized, a treatment effect of the same magnitude or
larger would have been observed.Robert W. Yeh, MD, MSc
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Occlusion Devices Versus
Pharmacological Agents
for Stroke Prevention in
Atrial FibrillationIn evaluating the effectiveness of the Watchman
appendage occlusion device (AOD) in patients with
